| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 10 | — | 17.8x | Bottom tier | |
Growth | 36 | -7.3% | 7.1% | Bottom tier | |
Quality | 30 | -159.9% | 4.5% | Bottom tier | |
Safety | 6 | — | 2.6x | Bottom tier | |
Capital Return | 40 | — | 2.12% | Around median | |
Momentum | 78 | 30.5% | 2.9% | Top tier | |
Sentiment | 93 | 10 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Kura Oncology is a commercial-stage oncology company building two growth franchises in precision therapies. The first franchise is based on Ziftomenib, marketed as KOMZIFTI for the treatment of relapsed or refractory NPM1-mutated acute myeloid leukemia, with a development program testing it as monotherapy and in combination with venetoclax, azacitidine, gilteritinib, and quizartinib. The second franchise is darlifarnib, a wholly owned asset being developed in combination regimens for renal cell carcinoma and KRAS G12C-mutated solid tumors, with additional opportunities under evaluation in KRAS-mutated pancreatic cancer.
In fiscal Q2 2026, total revenue was $20.9 million, comprising $9.1 million in KOMZIFTI net sales and $11.8 million in collaboration revenue from Kyowa Kirin; approximately 44% from the product and 56% from the collaboration. Gross profit was $20.6 million, representing a calculated gross margin of approximately 98.6%, but the company recorded a net loss of $68.3 million and negative earnings per share of $0.77. Selling, general, and administrative expenses increased to $31.8 million from $25.2 million in the comparable period, while research and development expenses declined slightly to $61.9 million from $62.8 million.
The commercial launch in fiscal Q2 2026 generated approximately 115 new patient starts and more than 250 total prescriptions, and management said KOMZIFTI captured the majority of new patient starts in the menin inhibitor market for relapsed or refractory NPM1 cases. New patient starts grew approximately 35% quarter over quarter, while total prescriptions increased approximately 60%, without a material one-time impact from inventory stocking. Coverage exceeded 95% of insured lives, with approximately 16 million people in a preferred position requiring them to try KOMZIFTI before other menin inhibitors.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” with an average price target of $22.89 and a wide range of $15 to $24; both the average and highest targets are above the 52-week range high of $13.9, versus a low of $7.358. No positive price-to-earnings multiple is available because of the twelve-month loss of $296.8 million, so the valuation depends more heavily on continued KOMZIFTI growth and the success of KOMET-017 and darlifarnib, while the wide range of targets highlights the degree of clinical and commercial uncertainty.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
KOMZIFTI recorded net product revenue of $9.1 million in its second full commercial quarter. New patient starts totaled approximately 115, and total prescriptions exceeded 250, with quarter-over-quarter growth of 35% and 60%, respectively. Management said the product captured the majority of new patient starts in the menin inhibitor market for relapsed or refractory NPM1 cases, without a material contribution from one-time inventory stocking.
In fiscal Q2 2026, KOMZIFTI coverage included more than 95% of insured lives without restrictions on the approved label, according to management. Approximately 16 million people had preferred coverage requiring them to try KOMZIFTI before receiving other menin inhibitors. The company said it had not seen challenges preventing physicians from providing the treatment to patients when going through prior authorization procedures.
KOMET-017 is testing the expansion of Ziftomenib into frontline treatment of acute myeloid leukemia through a design combining intensive and non-intensive chemotherapy tracks. The program is targeting more than 200 sites, and site activation and patient enrollment were ongoing in the United States, Europe, and Asia as of August 12, 2026. The company maintained its expectation of announcing the first topline results from the intensive chemotherapy track in 2028.
darlifarnib with cabozantinib achieved an objective response rate of 44% and a disease control rate of 94% among patients previously exposed to cabozantinib. Among 34 patients with advanced clear cell renal cell carcinoma who had not previously received cabozantinib, response ranged from 33% to 50%, and median progression-free survival was 13 months. In KRAS G12C cancers, its combination with adagrasib produced tumor shrinkage in 77% of response-evaluable patients.
Cash, cash equivalents, and short-term investments totaled $519 million on June 30, 2026, down from $667.2 million on December 31, 2025. The company also expects payments of $180 million under its agreement with Kyowa Kirin. According to management, these resources are sufficient to fund the Ziftomenib program in acute myeloid leukemia through the first topline results from the Phase 3 KOMET-017 trial expected in 2028, but this statement does not include a guarantee of funding all darlifarnib opportunities through registration.
Investors should monitor growth in KOMZIFTI net revenue from a base of $9.1 million, along with the relationship between patient starts, repeat prescriptions, and total prescriptions. They should also monitor the net loss of $68.3 million and selling, general, and administrative expenses, which increased to $31.8 million. The company maintained collaboration revenue guidance of $45 million to $55 million for fiscal 2026, followed by $90 million to $110 million for each of fiscal 2027 and fiscal 2028, while clarifying that this revenue represents non-cash accounting recognition of performance obligations.
